文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

成人ICU患者预防性使用泮托拉唑的治疗效应异质性:SUP-ICU试验的事后分析

Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial.
PubMed 文献 · Intensive Care Med · 2020-01-14
一句话结论SUP-ICU事后分析提示,病情越重或CIB风险因素越多的ICU患者使用泮托拉唑后严重不良事件风险可能升高,但该发现为假设生成性,需进一步前瞻性研究。

该研究为SUP-ICU试验的事后分析,纳入3291例有临床重要消化道出血(CIB)风险的成人ICU患者,比较预防性泮托拉唑与安慰剂。采用贝叶斯分层模型按SAPS II五分位和CIB风险因素总数评估异质性治疗效应(HTE)。结果显示,病情严重程度越高的患者使用泮托拉唑后90天死亡风险可能升高(亚组OR范围0.90-1.09),临床重要事件(OR 0.86-1.18)和感染性不良事件(OR 0.88-1.27)也呈现类似HTE;但泮托拉唑持续显著降低CIB风险(OR 0.53-0.63),无HTE迹象。作者认为这些发现为假设生成性,需进一步前瞻性研究。

要点

  • 在SUP-ICU试验的3291例成人ICU患者中,预防性泮托拉唑持续降低临床重要消化道出血风险(OR 0.53-0.63),未见HTE。
  • 按SAPS II五分位分层,病情最重患者使用泮托拉唑后90天死亡风险可能升高(亚组OR范围0.90-1.09),提示潜在HTE。
  • 病情严重程度更高或CIB风险因素更多的患者,使用泮托拉唑后临床重要事件(OR 0.86-1.18)和感染性不良事件(OR 0.88-1.27)风险可能更高。
  • 按CIB风险因素数量分层时,90天死亡未见HTE(OR 1.00-1.02)。
  • 作者指出上述HTE发现为假设生成性,需进一步前瞻性研究验证。

适用人群与场景

  • SUP-ICU试验纳入的3291例有临床重要消化道出血(CIB)风险的成人ICU患者。

研究设计与关键结果

  • 研究类型:SUP-ICU试验的事后分析,纳入3291例成人ICU患者,比较预防性泮托拉唑与安慰剂。
  • 主要分析:按SAPS II五分位和CIB风险因素总数,用贝叶斯分层模型评估HTE;连续尺度用带交互项的贝叶斯逻辑回归模型。
  • 90天死亡:按病情严重程度观察到潜在HTE(亚组OR中位范围0.90-1.09),病情最重者风险更高;按CIB风险因素数量未见HTE(OR 1.00-1.02)。
  • 临床重要事件:观察到潜在HTE(OR 0.86-1.18),病情更重和CIB风险因素更多者风险更高。
  • 感染性不良事件:观察到潜在HTE(OR 0.88-1.27),病情更重和CIB风险因素更多者风险更高。
  • 临床重要消化道出血(CIB):泮托拉唑显著且持续降低风险,无HTE迹象(OR 0.53-0.63)。

证据类型、等级与局限

  • 证据类型:SUP-ICU随机对照试验的事后分析。
  • 作者结论:发现HTE迹象,即病情更重或CIB风险因素更多的患者分配至泮托拉唑后严重不良事件风险增加;这些发现为假设生成性,需进一步前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,病情更重或CIB风险因素更多的ICU患者使用预防性泮托拉唑后严重不良事件风险可能增加,该发现为假设生成性,需进一步前瞻性研究。

指南或共识出处

  • SUP-ICU试验(Stress Ulcer Prophylaxis in the Intensive Care Unit),ClinicalTrials.gov标识NCT02467621。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) trial compared prophylactic pantoprazole with placebo in 3291 adult ICU patients at risk of clinically important gastrointestinal bleeding (CIB). As a predefined subgroup analysis suggested increased 90-day mortality with pantoprazole in the most severely ill patients, we aimed to further explore whether heterogenous treatment effects (HTE) were present.

METHODS: We assessed HTE in subgroups defined according to illness severity by SAPS II quintiles and the total number of risk factors for CIB using Bayesian hierarchical models, and on the continuous scale using Bayesian logistic regression models with interactions. Estimates were presented as posterior probability distributions of odds ratios (ORs), probabilities of different effect sizes, and marginal effects plots.

RESULTS: We observed potential HTE for 90-day mortality according to illness severity (median subgroup OR range 0.90-1.09) with higher risk in the most severely ill, but not with different numbers of risk factors (1.00-1.02). We observed potential HTE of pantoprazole for clinically important events (0.86-1.18) and infectious adverse events (0.88-1.27) with higher risk in patients with greater illness severity and in those with more risk factors for CIB. Pantoprazole substantially and consistently reduced the risk of CIB with no indications of HTE (0.53-0.63).

CONCLUSIONS: In this post hoc analysis of the SUP-ICU trial, we found indications of HTE with increased risks of serious adverse events in patients with greater illness severity or more risk factors for CIB allocated to pantoprazole. These findings are hypothesis-generating and warrant further prospective investigation. CLINICALTRIALS.

GOV IDENTIFIER: NCT02467621.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Granholm A, Marker S, Krag M, et al. Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial. Intensive Care Med. 2020. PMID: 31938829. doi:10.1007/s00134-019-05903-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。